Global Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Analysis

Dublin, Oct. 23, 2020 (GLOBE NEWSWIRE) -- The "Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type; Indication; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global late stage chronic kidney disease drugs market is expected to reach US$ 11,096.9 million by 2027 from US$ 4,680.0 million in 2019; it is estimated to grow at a CAGR of 11.6% from 2020 to 2027. The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth.

Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period. Factors such as high prevalence of hyperparathyroidism, increased research studies on calcimimetics are some of the impacting factors which drive the segment growth. For instance, in February 2017, Amgen received the US Food and Drug Administration (FDA) approval for Parsabiv, an etelcalcetide, for the treatment of secondary hyperparathyroidism (HPT) in adult patients with late stage chronic kidney disease receiving hemodialysis. Parsabiv is the first therapy approved for HPT in ESRD in 12 years. It is the only calcimimetic that is used for intravenous administration by the dialysis health care team thrice a week to the ending of the hemodialysis session.

The market growth is also attributed to a few key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.

AbbVie Inc.; Amgen; AstraZeneca; Sanofi; Kyowa Kirin Co., Ltd.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Bayer AG; Vifor Pharma Management Ltd.; and Akebia Drugs, Inc. are among the prominent players operating in the late stage chronic kidney disease drugs market. The market players are focused on organic strategies to sustain their position in the market. For instance, in Jul-2020, Bayer announced positive results from the Phase III FIDELIO-DKD study, assessing the efficacy and safety of finerenone versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the late stage chronic kidney disease drugs market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global late stage chronic kidney disease drugs market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction

2. Late Stage Chronic Kidney Disease Drugs Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Late Stage Chronic Kidney Disease Drugs Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia-Pacific - PEST Analysis
4.2.4 Middle East and Africa (MEA) - PEST Analysis
4.2.5 South & Central America (SCAM) - PEST Analysis
4.3 Expert Opinion

5. Late Stage Chronic Kidney Disease Drugs Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Diseases Leading to Chronic Kidney Diseases
5.1.2 Favourable Reimbursement Policy for the Late Stage Chronic Kidney Disease Drugs
5.2 Market Restraints
5.2.1 Delay in the Diagnosis of Chronic Kidney Disease
5.3 Market Opportunities
5.3.1 Introduction of New Late Stage Chronic Kidney Disease Drugs
5.4 Future Trends
5.4.1 Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development
5.5 Impact Analysis

6. Late Stage Chronic Kidney Disease Drugs Market - Global Analysis
6.1 Global Late Stage Chronic Kidney Disease Drugs Market Revenue Forecast And Analysis
6.2 Global Late Stage Chronic Kidney Disease Drugs Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Late Stage Chronic Kidney Disease Drugs Market Analysis - By Product Type
7.1 Overview
7.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
7.3 Calcimimetics
7.3.1 Overview
7.3.2 Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Vitamin D
7.4.1 Overview
7.4.2 Vitamin D: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Potassium Binders
7.5.1 Overview
7.5.2 Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
7.6 Calcium-Based Phosphate Binders
7.6.1 Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
7.7 Others
7.7.1 Others: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

8. Late Stage Chronic Kidney Disease Drugs Market Analysis By Indication
8.1 Overview
8.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
8.3 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
8.3.1 Overview
8.3.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
8.4.1 Overview
8.4.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Late Stage Chronic Kidney Disease Induced Hyperkalemia
8.5.1 Overview
8.5.2 Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

9. Late Stage Chronic Kidney Disease Drugs Market Analysis By Distribution Channel
9.1 Overview
9.2 Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Online Pharmacies
9.4.1 Overview
9.4.2 Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)
9.5 Retail Pharmacies
9.5.1 Overview
9.5.2 Retail Pharmacies Segment : Late Stage Chronic Kidney Disease Drugs Market - Revenue and Forecast to 2027 (US$ Million)

10. Late Stage Chronic Kidney Disease Drugs Market Analysis And Forecasts To 2027 - Geographical Analysis
10.1 North America: Late Stage Chronic Kidney Disease Drugs Market
10.2 Europe: Late Stage Chronic Kidney Disease Drugs Market
10.3 Asia-Pacific: Late Stage Chronic Kidney Disease Drugs Market
10.4 Middle East & Africa: Late Stage Chronic Kidney Disease Drugs Market
10.5 South and Central America: Late Stage Chronic Kidney Disease Drugs Market

11. Impact of COVID-19 Pandemic on Global Late Stage Chronic Kidney Disease Drugs Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Late Stage Chronic Kidney Disease Drugs Market - Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview

13. Company Profiles
13.1 AbbVie Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Amgen
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 AstraZeneca
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Kyowa Kirin Co., Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Takeda Pharmaceutical Company Limited
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Astellas Pharma Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Bayer AG
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Vifor Pharma Management Ltd.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Akebia Therapeutics, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix
14.1 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/omykte

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900